全文获取类型
收费全文 | 3010篇 |
免费 | 172篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 74篇 |
妇产科学 | 62篇 |
基础医学 | 503篇 |
口腔科学 | 106篇 |
临床医学 | 259篇 |
内科学 | 599篇 |
皮肤病学 | 35篇 |
神经病学 | 299篇 |
特种医学 | 117篇 |
外科学 | 300篇 |
综合类 | 19篇 |
预防医学 | 286篇 |
眼科学 | 31篇 |
药学 | 229篇 |
中国医学 | 22篇 |
肿瘤学 | 260篇 |
出版年
2023年 | 36篇 |
2022年 | 104篇 |
2021年 | 148篇 |
2020年 | 91篇 |
2019年 | 96篇 |
2018年 | 107篇 |
2017年 | 90篇 |
2016年 | 101篇 |
2015年 | 83篇 |
2014年 | 141篇 |
2013年 | 162篇 |
2012年 | 273篇 |
2011年 | 256篇 |
2010年 | 139篇 |
2009年 | 136篇 |
2008年 | 184篇 |
2007年 | 189篇 |
2006年 | 180篇 |
2005年 | 150篇 |
2004年 | 105篇 |
2003年 | 130篇 |
2002年 | 106篇 |
2001年 | 24篇 |
2000年 | 14篇 |
1999年 | 20篇 |
1998年 | 11篇 |
1997年 | 11篇 |
1996年 | 2篇 |
1995年 | 14篇 |
1994年 | 5篇 |
1993年 | 10篇 |
1992年 | 8篇 |
1991年 | 10篇 |
1990年 | 11篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 5篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1984年 | 6篇 |
1983年 | 6篇 |
1982年 | 2篇 |
1980年 | 3篇 |
1979年 | 7篇 |
1978年 | 2篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1972年 | 2篇 |
1970年 | 2篇 |
1969年 | 2篇 |
排序方式: 共有3210条查询结果,搜索用时 15 毫秒
61.
Fulvia Milena Cribi Roberta Erra Lorenza Pugni Carlota Rubio-Perez Lidia Alonso Sara Simonetti Giorgio Alberto Croci Garazi Serna Andrea Ronchi Carlo Pietrasanta Giovanna Lunghi Anna Maria Fagnani Maria Piana Matthias Matter Alexandar Tzankov Luigi Terracciano Andres Anton Enrico Ferrazzi Stefano Ferrero Enrico Iurlaro Joan Seoane Paolo Nuciforo 《The Journal of clinical investigation》2021,131(6)
62.
63.
64.
Ya-dong Gao Mei Ding Xiang Dong Jin-jin Zhang Ahmet Kursat Azkur Dilek Azkur Hui Gan Yuan-li Sun Wei Fu Wei Li Hui-ling Liang Yi-yuan Cao Qi Yan Can Cao Hong-yu Gao Marie-Charlotte Brüggen Willem van de Veen Milena Sokolowska Mübeccel Akdis Cezmi A. Akdis 《Allergy》2021,76(2):428-455
The pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused an unprecedented global social and economic impact, and high numbers of deaths. Many risk factors have been identified in the progression of COVID-19 into a severe and critical stage, including old age, male gender, underlying comorbidities such as hypertension, diabetes, obesity, chronic lung diseases, heart, liver and kidney diseases, tumors, clinically apparent immunodeficiencies, local immunodeficiencies, such as early type I interferon secretion capacity, and pregnancy. Possible complications include acute kidney injury, coagulation disorders, thoromboembolism. The development of lymphopenia and eosinopenia are laboratory indicators of COVID-19. Laboratory parameters to monitor disease progression include lactate dehydrogenase, procalcitonin, high-sensitivity C-reactive protein, proinflammatory cytokines such as interleukin (IL)-6, IL-1β, Krebs von den Lungen-6 (KL-6), and ferritin. The development of a cytokine storm and extensive chest computed tomography imaging patterns are indicators of a severe disease. In addition, socioeconomic status, diet, lifestyle, geographical differences, ethnicity, exposed viral load, day of initiation of treatment, and quality of health care have been reported to influence individual outcomes. In this review, we highlight the scientific evidence on the risk factors of severity of COVID-19. 相似文献
65.
Gerdien Tramper-Stranders Dominika Ambrożej Alessandra Arcolaci Marina Atanaskovic-Markovic Cristina Boccabella Matteo Bonini Aspasia Karavelia Ervin Mingomataj Liam O' Mahony Milena Sokolowska Eva Untersmayr Wojciech Feleszko the EAACI Task Force on Conscious Rational use of Antibiotics in Allergic Diseases 《Allergy》2021,76(11):3276-3291
Microbiota composition and associated metabolic activities are essential for the education and development of a healthy immune system. Microbial dysbiosis, caused by risk factors such as diet, birth mode, or early infant antimicrobial therapy, is associated with the inception of allergic diseases. In turn, allergic diseases increase the risk for irrational use of antimicrobial therapy. Microbial therapies, such as probiotics, have been studied in the prevention and treatment of allergic diseases, but evidence remains limited due to studies with high heterogeneity, strain-dependent effectiveness, and variable outcome measures. In this review, we sketch the relation of microbiota with allergic diseases, the overuse and rationale for the use of antimicrobial agents in allergic diseases, and current knowledge concerning the use of bacterial products in allergic diseases. We urgently recommend 1) limiting antibiotic therapy in pregnancy and early childhood as a method contributing to the reduction of the allergy epidemic in children and 2) restricting antibiotic therapy in exacerbations and chronic treatment of allergic diseases, mainly concerning asthma and atopic dermatitis. Future research should be aimed at antibiotic stewardship implementation strategies and biomarker-guided therapy, discerning those patients that might benefit from antibiotic therapy. 相似文献
66.
Marcelo de Lima Oliveira Daniel Silva de Azevedo Milena Krajnyk de Azevedo Ricardo de Carvalho Nogueira Manoel Jacobsen Teixeira Edson Bor-Seng-Shu 《中国神经再生研究》2015,10(5):748-752
Subarachnoid hemorrhage is frequently associated with poor prognoses. Three different hemodynamic phases were identified during subarachnoid hemorrhage: oligemia, hyperemia, and vasospasm. Each phase is associated with brain metabolic changes. In this review, we correlated the hemodynamic phases with brain metabolism and potential treatment options in the hopes of improving patient prognoses. 相似文献
67.
68.
Milena Dropa Barbara Ghiglione Maria Helena Matté Livia Carminato Balsalobre Nilton Lincopan Glavur Rogério Matté Gabriel Gutkind Pablo Power 《Antimicrobial agents and chemotherapy》2015,59(3):1815-1817
CTX-M-131 is a natural Asp240Gly variant from the CTX-M-2 group detected in a Providencia rettgeri clinical strain from Brazil. Molecular analysis showed that blaCTX-M-131 was inserted in a complex class 1 integron harbored by a 112-kb plasmid, which has not been previously described as a platform for CTX-M-encoding genes with the Asp240Gly mutation. Steady-state kinetic parameters showed that the enzyme has a typical cefotaximase catalytic profile and an enhanced activity against ceftazidime. 相似文献
69.
Giorgina Barbara Piccoli Gianfranca Cabiddu Rossella Attini Federica Neve Vigotti Stefania Maxia Nicola Lepori Milena Tuveri Marco Massidda Cecilia Marchi Silvia Mura Alessandra Coscia Marilisa Biolcati Pietro Gaglioti Michele Nichelatti Luciana Pibiri Giuseppe Chessa Antonello Pani Tullia Todros 《Journal of the American Society of Nephrology : JASN》2015,26(8):2011-2022
CKD is increasingly prevalent in pregnancy. In the Torino-Cagliari Observational Study (TOCOS), we assessed whether the risk for adverse pregnancy outcomes is associated with CKD by comparing pregnancy outcomes of 504 pregnancies in women with CKD to outcomes of 836 low-risk pregnancies in women without CKD. The presence of hypertension, proteinuria (>1 g/d), systemic disease, and CKD stage (at referral) were assessed at baseline. The following outcomes were studied: cesarean section, preterm delivery, and early preterm delivery; small for gestational age (SGA); need for neonatal intensive care unit (NICU); new onset of hypertension; new onset/doubling of proteinuria; CKD stage shift; “general” combined outcome (preterm delivery, NICU, SGA); and “severe” combined outcome (early preterm delivery, NICU, SGA). The risk for adverse outcomes increased across stages (for stage 1 versus stages 4–5: “general” combined outcome, 34.1% versus 90.0%; “severe” combined outcome, 21.4% versus 80.0%; P<0.001). In women with stage 1 CKD, preterm delivery was associated with baseline hypertension (odds ratio [OR], 3.42; 95% confidence interval [95% CI], 1.87 to 6.21), systemic disease (OR, 3.13; 95% CI, 1.51 to 6.50), and proteinuria (OR, 3.69; 95% CI, 1.63 to 8.36). However, stage 1 CKD remained associated with adverse pregnancy outcomes (general combined outcome) in women without baseline hypertension, proteinuria, or systemic disease (OR, 1.88; 95% CI, 1.27 to 2.79). The risk of intrauterine death did not differ between patients and controls. Findings from this prospective study suggest a “baseline risk” for adverse pregnancy-related outcomes linked to CKD. 相似文献
70.